Poeran Jashvant, Wasserman Isaac, Zubizarreta Nicole, Mazumdar Madhu
1 Institute for Healthcare Delivery Science, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York 2 Icahn School of Medicine at Mount Sinai, New York, New York.
Dis Colon Rectum. 2016 Aug;59(8):733-42. doi: 10.1097/DCR.0000000000000633.
Despite numerous trials assessing optimal antibiotic prophylaxis strategies for colorectal surgery, few studies have assessed real-world practice on a national scale with respect to risk of surgical site infections.
Using a large national claims database we aimed to describe current use of prophylactic antibiotics (type and duration) and associations with surgical site infection after open colectomies.
This was a retrospective study using the Premier Perspective database.
Included were patient hospitalizations nationwide from January 2006 to December 2013.
A total of 90,725 patients who underwent an open colectomy in 445 different hospitals were included in the study.
Multilevel, multivariable logistic regressions measured associations between surgical site infection and type of antibiotic used and duration (day of surgery only, day of surgery and the day after, and >1 day after surgery).
Overall surgical site infection prevalence was 5.2% (n = 4750). Most patients (41.8%) received cefoxitin for prophylaxis; other choices were ertapenem (18.2%), cefotetan (10.3%), metronidazole with cefazolin (9.9%), and ampicillin with sulbactam (7.6%), whereas 12.2% received other antibiotics. Distribution of prophylaxis duration was 51.6%, 28.5%, and 19.9% for day of surgery only, day of surgery and the day after, and >1 day after surgery, respectively. Compared with cefoxitin, lower odds for surgical site infection were observed for ampicillin with sulbactam (OR = 0.71 (95% CI, 0.63-0.82)), ertapenem (OR = 0.65 (95% CI, 0.58-0.71)), metronidazole with cefazolin (OR = 0.56 (95% CI, 0.49-0.64)), and "other" (OR = 0.81 (95% CI, 0.73-0.90)); duration was not significantly associated with altered odds for surgical site infection. Sensitivity analyses supported the main findings.
The study was limited by its lack of detailed clinical information in the billing data set used.
In this national study assessing real-world use of prophylactic antibiotics in open colectomies, the type of antibiotic used appeared to be associated with up to 44% decreased odds for surgical site infections. Although there are numerous trials on optimal prophylactic strategies, studies that particularly focus on factors that influence the choice of prophylactic antibiotic might provide insights into ways of reducing the burden of surgical site infections in colorectal surgeries.
尽管有众多试验评估结直肠手术的最佳抗生素预防策略,但很少有研究在全国范围内评估手术部位感染风险方面的实际应用情况。
利用一个大型国家索赔数据库,我们旨在描述预防性抗生素的当前使用情况(类型和持续时间)以及与开放性结肠切除术后手术部位感染的关联。
这是一项使用Premier Perspective数据库的回顾性研究。
纳入了2006年1月至2013年12月期间全国范围内的患者住院病例。
共有90725例在445家不同医院接受开放性结肠切除术的患者纳入研究。
多水平、多变量逻辑回归分析测量手术部位感染与所用抗生素类型和持续时间(仅手术日、手术日及术后第一天、术后>1天)之间的关联。
总体手术部位感染患病率为5.2%(n = 4750)。大多数患者(41.8%)接受头孢西丁进行预防;其他选择包括厄他培南(18.2%)、头孢替坦(10.3%)、甲硝唑联合头孢唑林(9.9%)以及氨苄西林联合舒巴坦(7.6%),而12.2%的患者接受其他抗生素。预防持续时间的分布分别为仅手术日51.6%、手术日及术后第一天28.5%、术后>1天19.9%。与头孢西丁相比,氨苄西林联合舒巴坦(OR = 0.71(95%CI,0.63 - 0.82))、厄他培南(OR = 0.65(95%CI,0.58 - 0.71))、甲硝唑联合头孢唑林(OR = 0.56(95%CI,0.49 - 0.64))以及“其他”(OR = 0.81(95%CI,0.73 - 0.90))的手术部位感染几率较低;持续时间与手术部位感染几率的改变无显著关联。敏感性分析支持主要研究结果。
该研究受到所用计费数据集中缺乏详细临床信息的限制。
在这项评估开放性结肠切除术中预防性抗生素实际应用情况的全国性研究中,所用抗生素类型似乎与手术部位感染几率降低高达44%相关。尽管有众多关于最佳预防策略的试验,但特别关注影响预防性抗生素选择因素的研究可能会为减轻结直肠手术中手术部位感染负担的方法提供见解。